Review



interleukin 13 il 13  (MedChemExpress)


Bioz Verified Symbol MedChemExpress is a verified supplier
Bioz Manufacturer Symbol MedChemExpress manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 95
      Buy from Supplier

    Structured Review

    MedChemExpress interleukin 13 il 13
    THP-1 cells were treated under different conditions: PMA (50 ng/ml) alone, or PMA (50 ng/ml) for 24 hours, followed by a medium change and subsequent treatment with IL-4 (20 ng/ml) <t>and</t> <t>IL-13</t> (20 ng/ml) for 48 hours. After this, the medium was replaced with RPMI 1640 medium without FBS for 24 hours. Protein and mRNA were then extracted, and the supernatant was collected. (A) Morphological features of THP-1 cells under different conditions. Left: untreated THP-1 cells. Middle: PMA (50 ng/ml) for 24 hours. Right: PMA for 24 hours, followed by IL-4 and IL-13 (20 ng/ml) and IL-13 (20 ng/ml) for 48 hours. Scale bar: 50 μm. (B) Relative expression of Arg1 mRNA. (C) Relative expression of Arg1 protein. (D) Concentrations of TNF and IL-10 in the supernatant. (E) Relative mRNA expression of JMJD3 and IRF4. (F) Protein expression of JMJD3, p-STAT6-Y641, and IRF4. The experiments were replicated three times. * p < 0.05, ** p < 0.01, ***p < 0.001, ****p < 0.0001. Abbreviations: Arg1, arginase 1; PMA, Phorbol 12-myristate 13-acetate; IL-10, interleukin-10; TNF, tumor necrosis factor; JMJD3, Jumonji domain-containing protein 3; IRF4, interferon regulatory factor 4; p-STAT6, phosphorylated signal transducer and activator of transcription 6.
    Interleukin 13 Il 13, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 95/100, based on 8 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/interleukin+13+il+13/IL-13%2C+Human/pmc13065056-41-18-23
    Average 95 stars, based on 8 article reviews
    interleukin 13 il 13 - by Bioz Stars, 2026-10
    95/100 stars

    Images

    1) Product Images from "JMJD3 regulates the M2-like macrophage polarization and promotes the growth of breast cancer cells via STAT6/IRF4 axis"

    Article Title: JMJD3 regulates the M2-like macrophage polarization and promotes the growth of breast cancer cells via STAT6/IRF4 axis

    Journal: PLOS One

    doi: 10.1371/journal.pone.0341313

    THP-1 cells were treated under different conditions: PMA (50 ng/ml) alone, or PMA (50 ng/ml) for 24 hours, followed by a medium change and subsequent treatment with IL-4 (20 ng/ml) and IL-13 (20 ng/ml) for 48 hours. After this, the medium was replaced with RPMI 1640 medium without FBS for 24 hours. Protein and mRNA were then extracted, and the supernatant was collected. (A) Morphological features of THP-1 cells under different conditions. Left: untreated THP-1 cells. Middle: PMA (50 ng/ml) for 24 hours. Right: PMA for 24 hours, followed by IL-4 and IL-13 (20 ng/ml) and IL-13 (20 ng/ml) for 48 hours. Scale bar: 50 μm. (B) Relative expression of Arg1 mRNA. (C) Relative expression of Arg1 protein. (D) Concentrations of TNF and IL-10 in the supernatant. (E) Relative mRNA expression of JMJD3 and IRF4. (F) Protein expression of JMJD3, p-STAT6-Y641, and IRF4. The experiments were replicated three times. * p < 0.05, ** p < 0.01, ***p < 0.001, ****p < 0.0001. Abbreviations: Arg1, arginase 1; PMA, Phorbol 12-myristate 13-acetate; IL-10, interleukin-10; TNF, tumor necrosis factor; JMJD3, Jumonji domain-containing protein 3; IRF4, interferon regulatory factor 4; p-STAT6, phosphorylated signal transducer and activator of transcription 6.
    Figure Legend Snippet: THP-1 cells were treated under different conditions: PMA (50 ng/ml) alone, or PMA (50 ng/ml) for 24 hours, followed by a medium change and subsequent treatment with IL-4 (20 ng/ml) and IL-13 (20 ng/ml) for 48 hours. After this, the medium was replaced with RPMI 1640 medium without FBS for 24 hours. Protein and mRNA were then extracted, and the supernatant was collected. (A) Morphological features of THP-1 cells under different conditions. Left: untreated THP-1 cells. Middle: PMA (50 ng/ml) for 24 hours. Right: PMA for 24 hours, followed by IL-4 and IL-13 (20 ng/ml) and IL-13 (20 ng/ml) for 48 hours. Scale bar: 50 μm. (B) Relative expression of Arg1 mRNA. (C) Relative expression of Arg1 protein. (D) Concentrations of TNF and IL-10 in the supernatant. (E) Relative mRNA expression of JMJD3 and IRF4. (F) Protein expression of JMJD3, p-STAT6-Y641, and IRF4. The experiments were replicated three times. * p < 0.05, ** p < 0.01, ***p < 0.001, ****p < 0.0001. Abbreviations: Arg1, arginase 1; PMA, Phorbol 12-myristate 13-acetate; IL-10, interleukin-10; TNF, tumor necrosis factor; JMJD3, Jumonji domain-containing protein 3; IRF4, interferon regulatory factor 4; p-STAT6, phosphorylated signal transducer and activator of transcription 6.

    Techniques Used: Expressing

    (A) THP-1 cells were infected with shJMJD3 or oeJMJD3 lentiviruses for 72 hours. JMJD3 mRNA expression was then assessed. shCtrl and oeCtrl: negative control lentiviruses. shJMJD3: THP-1 cells infected with lentiviruses to knockdown JMJD3. oeJMJD3: THP-1 cells infected with lentiviruses to overexpress JMJD3. Following lentivirus infection, THP-1 cells were treated with PMA for 24 hours, followed by IL-4 and IL-13 for 48 hours. After this, the medium was replaced by RPMI 1640 medium without FBS for an additional 24 hours. Protein and mRNA were then extracted, and the supernatant was collected. (B) Relative expression of Arg1 mRNA. (C) Concentrations of TNF in the supernatant of different groups of macrophages. (D) Relative expression of IRF4 mRNA. (E, F) Western blot analysis of CD206, JMJD3, and IRF4 protein. The experiments were replicated three times. * p < 0.05, ** p < 0.01, ***p < 0.001, ****p < 0.0001. Abbreviations: JMJD3, Jumonji domain-containing protein 3; Arg1, arginase 1; TNF, tumor necrosis factor; IRF4, interferon regulatory factor 4; CD206, cluster of differentiation 206.
    Figure Legend Snippet: (A) THP-1 cells were infected with shJMJD3 or oeJMJD3 lentiviruses for 72 hours. JMJD3 mRNA expression was then assessed. shCtrl and oeCtrl: negative control lentiviruses. shJMJD3: THP-1 cells infected with lentiviruses to knockdown JMJD3. oeJMJD3: THP-1 cells infected with lentiviruses to overexpress JMJD3. Following lentivirus infection, THP-1 cells were treated with PMA for 24 hours, followed by IL-4 and IL-13 for 48 hours. After this, the medium was replaced by RPMI 1640 medium without FBS for an additional 24 hours. Protein and mRNA were then extracted, and the supernatant was collected. (B) Relative expression of Arg1 mRNA. (C) Concentrations of TNF in the supernatant of different groups of macrophages. (D) Relative expression of IRF4 mRNA. (E, F) Western blot analysis of CD206, JMJD3, and IRF4 protein. The experiments were replicated three times. * p < 0.05, ** p < 0.01, ***p < 0.001, ****p < 0.0001. Abbreviations: JMJD3, Jumonji domain-containing protein 3; Arg1, arginase 1; TNF, tumor necrosis factor; IRF4, interferon regulatory factor 4; CD206, cluster of differentiation 206.

    Techniques Used: Infection, Expressing, Negative Control, Knockdown, Western Blot

    THP-1 cells were first treated with PMA for 24 hours. Following this, AS1517499 (1μM) was administered for 30 minutes, and then the cells were treated with IL-4 and IL-13. 48 hours later, the medium was replaced with RPMI 1640 medium without FBS and cells were incubated for an additional 24 hours. Protein and mRNA were then extracted, and the supernatant was collected. (A) The mRNA expression of Arg1. (B) Concentrations of TNF in the supernatant of different groups of macrophages. (C) Concentrations of IL-10 in the supernatant of different groups of macrophages. (D) Expression of IRF4 mRNA. (E) Expression of JMJD3 mRNA. (F) Western blot analysis of JMJD3, p-STAT6, and IRF4 protein expression. The experiments were replicated three times. * p < 0.05, ** p < 0.01, ***p < 0.001, ****p < 0.0001. Abbreviations: JMJD3, Jumonji domain-containing protein 3; Arg1, arginase 1; TNF, tumor necrosis factor; IRF4, interferon regulatory factor 4; IL-10, interleukin-10; p-STAT6, phosphorylated signal transducer and activator of transcription 6.
    Figure Legend Snippet: THP-1 cells were first treated with PMA for 24 hours. Following this, AS1517499 (1μM) was administered for 30 minutes, and then the cells were treated with IL-4 and IL-13. 48 hours later, the medium was replaced with RPMI 1640 medium without FBS and cells were incubated for an additional 24 hours. Protein and mRNA were then extracted, and the supernatant was collected. (A) The mRNA expression of Arg1. (B) Concentrations of TNF in the supernatant of different groups of macrophages. (C) Concentrations of IL-10 in the supernatant of different groups of macrophages. (D) Expression of IRF4 mRNA. (E) Expression of JMJD3 mRNA. (F) Western blot analysis of JMJD3, p-STAT6, and IRF4 protein expression. The experiments were replicated three times. * p < 0.05, ** p < 0.01, ***p < 0.001, ****p < 0.0001. Abbreviations: JMJD3, Jumonji domain-containing protein 3; Arg1, arginase 1; TNF, tumor necrosis factor; IRF4, interferon regulatory factor 4; IL-10, interleukin-10; p-STAT6, phosphorylated signal transducer and activator of transcription 6.

    Techniques Used: Incubation, Expressing, Western Blot

    Related Articles

    other:

    Article Title: Transcriptome analysis combined with single-cell analysis identified that APOC1 influences cholesterol transport by macrophages in ccRCC.
    Article Snippet: To induce differentiation into M2 macrophages, THP-1 cells were first exposed to 100 ng/mL phorbol 12-myristate 13-acetate (PMA) (MedChemExpress, USA) for a period of 24 h. Following this, the cells were further stimulated with a combination of 10 ng/mL interleukin-13 (IL-13) and 10 ng/mL interleukin-4 (IL-4) (both from MedChemExpress, USA) for an additional 48 h.

    Article Title: Transcriptome analysis combined with single-cell analysis identified that APOC1 influences cholesterol transport by macrophages in ccRCC
    Article Snippet: To induce differentiation into M2 macrophages, THP-1 cells were first exposed to 100 ng/mL phorbol 12-myristate 13-acetate (PMA) (MedChemExpress, USA) for a period of 24 h. Following this, the cells were further stimulated with a combination of 10 ng/mL interleukin-13 (IL-13) and 10 ng/mL interleukin-4 (IL-4) (both from MedChemExpress, USA) for an additional 48 h.

    Pore Size:

    Article Title: Kynurenine facilitates renal cell carcinoma progression by suppressing M2 macrophage pyroptosis through inhibition of CASP1 cleavage
    Article Snippet: .. M2 polarization was induced by treatment with interleukin-4 (IL-4) and interleukin-13 (IL-13) (20 ng/mL each) for 72 h. M2 macrophages were pre-treated with 50 μM pyroptosis inhibitor VX-765 (MedChemExpress, Monmouth Junction, NJ, USA), 10 μM ferroptosis inhibitor Fer-1, or 20 μM apoptosis inhibitor Z-VAD-FMK for 4 h. M2 macrophages were exposed to kynurenine at concentrations of 0.25, 0.5, 1, or 2 mmol/L for 48 h. To assess tumor cell behavior in co-culture with M2 macrophages, Transwell inserts with 0.4 μm pore size were utilized. ..

    Cell Culture:

    Article Title: Cortical Actin Depolymerisation in 3D Cell Culture Enhances Extracellular Vesicle Secretion and Therapeutic Effects
    Article Snippet: The collected medium underwent centrifugation, and the resulting cell pellet was treated with red blood cell lysis buffer (FreeMoreBio, FK13415) for 15 min. After another round of centrifugation, the cell pellet was resuspended in culture medium containing 30 ng/mL colony-stimulating factor (CSF) (Biolegend, 556902) and cultured for 3 days. .. To induce differentiation into M1 or M2 phenotypes, BMDMs were cultured for one day in medium containing 1 μg/mL lipopolysaccharide (LPS) (Solarbio, L8880) + 10 ng/mL interferon-gamma (IFN-γ) (InvivoGen, P01579) for M1, or 4 ng/mL interleukin4 (IL-4) (ThermoFisherScientific, 200-04-1MG) + 4 ng/mL interleukin-13 (IL-13) (MCE, HEK293) for M2. ..

    Article Title: Cucurbitacin B suppresses malignant progression of oral leukoplakia via ferroptosis-induced macrophage polarization.
    Article Snippet: M2 macrophage, which can promote oral leukoplakia (OLK) development and progression, is considered a new potential target for the treatment and prevention of OLK malignant progression.. Cucurbitacin B (CuB), a tetracyclic triterpenoid compound widely found in cucurbit plants, has shown promising immunomodulatory and anti-proliferative efficacy in previous studies.. However, whether CuB can inhibit OLK malignant progression by modulating M2 macrophage polarization remains unclear.



    Similar Products

    mouse il-13 (interleukin 13) elisa kit  (Guangzhou JET Bio-Filtration)
    94
    Guangzhou JET Bio-Filtration mouse il-13 (interleukin 13) elisa kit
    Mouse Il 13 (Interleukin 13) Elisa Kit, supplied by Guangzhou JET Bio-Filtration, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/interleukin+13+il+13/Mouse+IL-13+(Interleukin+13)+ELISA+Kit/custom%40e-el-m0727%4042002123
    Average 94 stars, based on 1 article reviews
    mouse il-13 (interleukin 13) elisa kit - by Bioz Stars, 2026-10
    94/100 stars
    		  Buy from Supplier
    interleukin 13 il 13  (MedChemExpress)
    95
    MedChemExpress interleukin 13 il 13
    THP-1 cells were treated under different conditions: PMA (50 ng/ml) alone, or PMA (50 ng/ml) for 24 hours, followed by a medium change and subsequent treatment with IL-4 (20 ng/ml) <t>and</t> <t>IL-13</t> (20 ng/ml) for 48 hours. After this, the medium was replaced with RPMI 1640 medium without FBS for 24 hours. Protein and mRNA were then extracted, and the supernatant was collected. (A) Morphological features of THP-1 cells under different conditions. Left: untreated THP-1 cells. Middle: PMA (50 ng/ml) for 24 hours. Right: PMA for 24 hours, followed by IL-4 and IL-13 (20 ng/ml) and IL-13 (20 ng/ml) for 48 hours. Scale bar: 50 μm. (B) Relative expression of Arg1 mRNA. (C) Relative expression of Arg1 protein. (D) Concentrations of TNF and IL-10 in the supernatant. (E) Relative mRNA expression of JMJD3 and IRF4. (F) Protein expression of JMJD3, p-STAT6-Y641, and IRF4. The experiments were replicated three times. * p < 0.05, ** p < 0.01, ***p < 0.001, ****p < 0.0001. Abbreviations: Arg1, arginase 1; PMA, Phorbol 12-myristate 13-acetate; IL-10, interleukin-10; TNF, tumor necrosis factor; JMJD3, Jumonji domain-containing protein 3; IRF4, interferon regulatory factor 4; p-STAT6, phosphorylated signal transducer and activator of transcription 6.
    Interleukin 13 Il 13, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/interleukin+13+il+13/IL-13%2C+Human/pmc13065056-41-18-23
    Average 95 stars, based on 1 article reviews
    interleukin 13 il 13 - by Bioz Stars, 2026-10
    95/100 stars
    		  Buy from Supplier
    elisa kits  (Elabscience Biotechnology)
    94
    Elabscience Biotechnology elisa kits
    THP-1 cells were treated under different conditions: PMA (50 ng/ml) alone, or PMA (50 ng/ml) for 24 hours, followed by a medium change and subsequent treatment with IL-4 (20 ng/ml) <t>and</t> <t>IL-13</t> (20 ng/ml) for 48 hours. After this, the medium was replaced with RPMI 1640 medium without FBS for 24 hours. Protein and mRNA were then extracted, and the supernatant was collected. (A) Morphological features of THP-1 cells under different conditions. Left: untreated THP-1 cells. Middle: PMA (50 ng/ml) for 24 hours. Right: PMA for 24 hours, followed by IL-4 and IL-13 (20 ng/ml) and IL-13 (20 ng/ml) for 48 hours. Scale bar: 50 μm. (B) Relative expression of Arg1 mRNA. (C) Relative expression of Arg1 protein. (D) Concentrations of TNF and IL-10 in the supernatant. (E) Relative mRNA expression of JMJD3 and IRF4. (F) Protein expression of JMJD3, p-STAT6-Y641, and IRF4. The experiments were replicated three times. * p < 0.05, ** p < 0.01, ***p < 0.001, ****p < 0.0001. Abbreviations: Arg1, arginase 1; PMA, Phorbol 12-myristate 13-acetate; IL-10, interleukin-10; TNF, tumor necrosis factor; JMJD3, Jumonji domain-containing protein 3; IRF4, interferon regulatory factor 4; p-STAT6, phosphorylated signal transducer and activator of transcription 6.
    Elisa Kits, supplied by Elabscience Biotechnology, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/interleukin+13+il+13/Mouse+IL-13+(Interleukin+13)+ELISA+Kit/pm42002123-99-5-12
    Average 94 stars, based on 1 article reviews
    elisa kits - by Bioz Stars, 2026-10
    94/100 stars
    		  Buy from Supplier
    il 13 elisa kits  (Krishgen Biosystems)
    91
    Krishgen Biosystems il 13 elisa kits
    THP-1 cells were treated under different conditions: PMA (50 ng/ml) alone, or PMA (50 ng/ml) for 24 hours, followed by a medium change and subsequent treatment with IL-4 (20 ng/ml) <t>and</t> <t>IL-13</t> (20 ng/ml) for 48 hours. After this, the medium was replaced with RPMI 1640 medium without FBS for 24 hours. Protein and mRNA were then extracted, and the supernatant was collected. (A) Morphological features of THP-1 cells under different conditions. Left: untreated THP-1 cells. Middle: PMA (50 ng/ml) for 24 hours. Right: PMA for 24 hours, followed by IL-4 and IL-13 (20 ng/ml) and IL-13 (20 ng/ml) for 48 hours. Scale bar: 50 μm. (B) Relative expression of Arg1 mRNA. (C) Relative expression of Arg1 protein. (D) Concentrations of TNF and IL-10 in the supernatant. (E) Relative mRNA expression of JMJD3 and IRF4. (F) Protein expression of JMJD3, p-STAT6-Y641, and IRF4. The experiments were replicated three times. * p < 0.05, ** p < 0.01, ***p < 0.001, ****p < 0.0001. Abbreviations: Arg1, arginase 1; PMA, Phorbol 12-myristate 13-acetate; IL-10, interleukin-10; TNF, tumor necrosis factor; JMJD3, Jumonji domain-containing protein 3; IRF4, interferon regulatory factor 4; p-STAT6, phosphorylated signal transducer and activator of transcription 6.
    Il 13 Elisa Kits, supplied by Krishgen Biosystems, used in various techniques. Bioz Stars score: 91/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/interleukin+13+il+13/GENLISA+Rat+Interleukin+13+(IL-13+%2F+IL13)+ELISA/10__1007_slash_s11033___026___11708___y-52-4-7
    Average 91 stars, based on 1 article reviews
    il 13 elisa kits - by Bioz Stars, 2026-10
    91/100 stars
    		  Buy from Supplier
    interleukin 13  (MedChemExpress)
    95
    MedChemExpress interleukin 13
    THP-1 cells were treated under different conditions: PMA (50 ng/ml) alone, or PMA (50 ng/ml) for 24 hours, followed by a medium change and subsequent treatment with IL-4 (20 ng/ml) <t>and</t> <t>IL-13</t> (20 ng/ml) for 48 hours. After this, the medium was replaced with RPMI 1640 medium without FBS for 24 hours. Protein and mRNA were then extracted, and the supernatant was collected. (A) Morphological features of THP-1 cells under different conditions. Left: untreated THP-1 cells. Middle: PMA (50 ng/ml) for 24 hours. Right: PMA for 24 hours, followed by IL-4 and IL-13 (20 ng/ml) and IL-13 (20 ng/ml) for 48 hours. Scale bar: 50 μm. (B) Relative expression of Arg1 mRNA. (C) Relative expression of Arg1 protein. (D) Concentrations of TNF and IL-10 in the supernatant. (E) Relative mRNA expression of JMJD3 and IRF4. (F) Protein expression of JMJD3, p-STAT6-Y641, and IRF4. The experiments were replicated three times. * p < 0.05, ** p < 0.01, ***p < 0.001, ****p < 0.0001. Abbreviations: Arg1, arginase 1; PMA, Phorbol 12-myristate 13-acetate; IL-10, interleukin-10; TNF, tumor necrosis factor; JMJD3, Jumonji domain-containing protein 3; IRF4, interferon regulatory factor 4; p-STAT6, phosphorylated signal transducer and activator of transcription 6.
    Interleukin 13, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/interleukin+13+il+13/IL-13%2C+Human/pm42002048-273-57-59
    Average 95 stars, based on 1 article reviews
    interleukin 13 - by Bioz Stars, 2026-10
    95/100 stars
    		  Buy from Supplier
    cytokines il 13  (Elabscience Biotechnology)
    94
    Elabscience Biotechnology cytokines il 13
    THP-1 cells were treated under different conditions: PMA (50 ng/ml) alone, or PMA (50 ng/ml) for 24 hours, followed by a medium change and subsequent treatment with IL-4 (20 ng/ml) <t>and</t> <t>IL-13</t> (20 ng/ml) for 48 hours. After this, the medium was replaced with RPMI 1640 medium without FBS for 24 hours. Protein and mRNA were then extracted, and the supernatant was collected. (A) Morphological features of THP-1 cells under different conditions. Left: untreated THP-1 cells. Middle: PMA (50 ng/ml) for 24 hours. Right: PMA for 24 hours, followed by IL-4 and IL-13 (20 ng/ml) and IL-13 (20 ng/ml) for 48 hours. Scale bar: 50 μm. (B) Relative expression of Arg1 mRNA. (C) Relative expression of Arg1 protein. (D) Concentrations of TNF and IL-10 in the supernatant. (E) Relative mRNA expression of JMJD3 and IRF4. (F) Protein expression of JMJD3, p-STAT6-Y641, and IRF4. The experiments were replicated three times. * p < 0.05, ** p < 0.01, ***p < 0.001, ****p < 0.0001. Abbreviations: Arg1, arginase 1; PMA, Phorbol 12-myristate 13-acetate; IL-10, interleukin-10; TNF, tumor necrosis factor; JMJD3, Jumonji domain-containing protein 3; IRF4, interferon regulatory factor 4; p-STAT6, phosphorylated signal transducer and activator of transcription 6.
    Cytokines Il 13, supplied by Elabscience Biotechnology, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/interleukin+13+il+13/Mouse+IL-13+(Interleukin+13)+ELISA+Kit/pm42002123-99-9-12
    Average 94 stars, based on 1 article reviews
    cytokines il 13 - by Bioz Stars, 2026-10
    94/100 stars
    		  Buy from Supplier
    il 13  (Elabscience Biotechnology)
    94
    Elabscience Biotechnology il 13
    THP-1 cells were treated under different conditions: PMA (50 ng/ml) alone, or PMA (50 ng/ml) for 24 hours, followed by a medium change and subsequent treatment with IL-4 (20 ng/ml) <t>and</t> <t>IL-13</t> (20 ng/ml) for 48 hours. After this, the medium was replaced with RPMI 1640 medium without FBS for 24 hours. Protein and mRNA were then extracted, and the supernatant was collected. (A) Morphological features of THP-1 cells under different conditions. Left: untreated THP-1 cells. Middle: PMA (50 ng/ml) for 24 hours. Right: PMA for 24 hours, followed by IL-4 and IL-13 (20 ng/ml) and IL-13 (20 ng/ml) for 48 hours. Scale bar: 50 μm. (B) Relative expression of Arg1 mRNA. (C) Relative expression of Arg1 protein. (D) Concentrations of TNF and IL-10 in the supernatant. (E) Relative mRNA expression of JMJD3 and IRF4. (F) Protein expression of JMJD3, p-STAT6-Y641, and IRF4. The experiments were replicated three times. * p < 0.05, ** p < 0.01, ***p < 0.001, ****p < 0.0001. Abbreviations: Arg1, arginase 1; PMA, Phorbol 12-myristate 13-acetate; IL-10, interleukin-10; TNF, tumor necrosis factor; JMJD3, Jumonji domain-containing protein 3; IRF4, interferon regulatory factor 4; p-STAT6, phosphorylated signal transducer and activator of transcription 6.
    Il 13, supplied by Elabscience Biotechnology, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/interleukin+13+il+13/Mouse+IL-13+(Interleukin+13)+ELISA+Kit/pm41924773-104-12-19
    Average 94 stars, based on 1 article reviews
    il 13 - by Bioz Stars, 2026-10
    94/100 stars
    		  Buy from Supplier
    il 13 elisa kit  (Elabscience Biotechnology)
    94
    Elabscience Biotechnology il 13 elisa kit
    THP-1 cells were treated under different conditions: PMA (50 ng/ml) alone, or PMA (50 ng/ml) for 24 hours, followed by a medium change and subsequent treatment with IL-4 (20 ng/ml) <t>and</t> <t>IL-13</t> (20 ng/ml) for 48 hours. After this, the medium was replaced with RPMI 1640 medium without FBS for 24 hours. Protein and mRNA were then extracted, and the supernatant was collected. (A) Morphological features of THP-1 cells under different conditions. Left: untreated THP-1 cells. Middle: PMA (50 ng/ml) for 24 hours. Right: PMA for 24 hours, followed by IL-4 and IL-13 (20 ng/ml) and IL-13 (20 ng/ml) for 48 hours. Scale bar: 50 μm. (B) Relative expression of Arg1 mRNA. (C) Relative expression of Arg1 protein. (D) Concentrations of TNF and IL-10 in the supernatant. (E) Relative mRNA expression of JMJD3 and IRF4. (F) Protein expression of JMJD3, p-STAT6-Y641, and IRF4. The experiments were replicated three times. * p < 0.05, ** p < 0.01, ***p < 0.001, ****p < 0.0001. Abbreviations: Arg1, arginase 1; PMA, Phorbol 12-myristate 13-acetate; IL-10, interleukin-10; TNF, tumor necrosis factor; JMJD3, Jumonji domain-containing protein 3; IRF4, interferon regulatory factor 4; p-STAT6, phosphorylated signal transducer and activator of transcription 6.
    Il 13 Elisa Kit, supplied by Elabscience Biotechnology, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/interleukin+13+il+13/Human+IL-13+(Interleukin+13)+ELISA+Kit/pmc13008083-72-5-8
    Average 94 stars, based on 1 article reviews
    il 13 elisa kit - by Bioz Stars, 2026-10
    94/100 stars
    		  Buy from Supplier
    human il 13  (Elabscience Biotechnology)
    94
    Elabscience Biotechnology human il 13
    THP-1 cells were treated under different conditions: PMA (50 ng/ml) alone, or PMA (50 ng/ml) for 24 hours, followed by a medium change and subsequent treatment with IL-4 (20 ng/ml) <t>and</t> <t>IL-13</t> (20 ng/ml) for 48 hours. After this, the medium was replaced with RPMI 1640 medium without FBS for 24 hours. Protein and mRNA were then extracted, and the supernatant was collected. (A) Morphological features of THP-1 cells under different conditions. Left: untreated THP-1 cells. Middle: PMA (50 ng/ml) for 24 hours. Right: PMA for 24 hours, followed by IL-4 and IL-13 (20 ng/ml) and IL-13 (20 ng/ml) for 48 hours. Scale bar: 50 μm. (B) Relative expression of Arg1 mRNA. (C) Relative expression of Arg1 protein. (D) Concentrations of TNF and IL-10 in the supernatant. (E) Relative mRNA expression of JMJD3 and IRF4. (F) Protein expression of JMJD3, p-STAT6-Y641, and IRF4. The experiments were replicated three times. * p < 0.05, ** p < 0.01, ***p < 0.001, ****p < 0.0001. Abbreviations: Arg1, arginase 1; PMA, Phorbol 12-myristate 13-acetate; IL-10, interleukin-10; TNF, tumor necrosis factor; JMJD3, Jumonji domain-containing protein 3; IRF4, interferon regulatory factor 4; p-STAT6, phosphorylated signal transducer and activator of transcription 6.
    Human Il 13, supplied by Elabscience Biotechnology, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/interleukin+13+il+13/Human+IL-13+(Interleukin+13)+ELISA+Kit/pmc12968724-48-6-12
    Average 94 stars, based on 1 article reviews
    human il 13 - by Bioz Stars, 2026-10
    94/100 stars
    		  Buy from Supplier

    Image Search Results


    THP-1 cells were treated under different conditions: PMA (50 ng/ml) alone, or PMA (50 ng/ml) for 24 hours, followed by a medium change and subsequent treatment with IL-4 (20 ng/ml) and IL-13 (20 ng/ml) for 48 hours. After this, the medium was replaced with RPMI 1640 medium without FBS for 24 hours. Protein and mRNA were then extracted, and the supernatant was collected. (A) Morphological features of THP-1 cells under different conditions. Left: untreated THP-1 cells. Middle: PMA (50 ng/ml) for 24 hours. Right: PMA for 24 hours, followed by IL-4 and IL-13 (20 ng/ml) and IL-13 (20 ng/ml) for 48 hours. Scale bar: 50 μm. (B) Relative expression of Arg1 mRNA. (C) Relative expression of Arg1 protein. (D) Concentrations of TNF and IL-10 in the supernatant. (E) Relative mRNA expression of JMJD3 and IRF4. (F) Protein expression of JMJD3, p-STAT6-Y641, and IRF4. The experiments were replicated three times. * p < 0.05, ** p < 0.01, ***p < 0.001, ****p < 0.0001. Abbreviations: Arg1, arginase 1; PMA, Phorbol 12-myristate 13-acetate; IL-10, interleukin-10; TNF, tumor necrosis factor; JMJD3, Jumonji domain-containing protein 3; IRF4, interferon regulatory factor 4; p-STAT6, phosphorylated signal transducer and activator of transcription 6.

    Journal: PLOS One

    Article Title: JMJD3 regulates the M2-like macrophage polarization and promotes the growth of breast cancer cells via STAT6/IRF4 axis

    doi: 10.1371/journal.pone.0341313

    Figure Lengend Snippet: THP-1 cells were treated under different conditions: PMA (50 ng/ml) alone, or PMA (50 ng/ml) for 24 hours, followed by a medium change and subsequent treatment with IL-4 (20 ng/ml) and IL-13 (20 ng/ml) for 48 hours. After this, the medium was replaced with RPMI 1640 medium without FBS for 24 hours. Protein and mRNA were then extracted, and the supernatant was collected. (A) Morphological features of THP-1 cells under different conditions. Left: untreated THP-1 cells. Middle: PMA (50 ng/ml) for 24 hours. Right: PMA for 24 hours, followed by IL-4 and IL-13 (20 ng/ml) and IL-13 (20 ng/ml) for 48 hours. Scale bar: 50 μm. (B) Relative expression of Arg1 mRNA. (C) Relative expression of Arg1 protein. (D) Concentrations of TNF and IL-10 in the supernatant. (E) Relative mRNA expression of JMJD3 and IRF4. (F) Protein expression of JMJD3, p-STAT6-Y641, and IRF4. The experiments were replicated three times. * p < 0.05, ** p < 0.01, ***p < 0.001, ****p < 0.0001. Abbreviations: Arg1, arginase 1; PMA, Phorbol 12-myristate 13-acetate; IL-10, interleukin-10; TNF, tumor necrosis factor; JMJD3, Jumonji domain-containing protein 3; IRF4, interferon regulatory factor 4; p-STAT6, phosphorylated signal transducer and activator of transcription 6.

    Article Snippet: Subsequently, the cells were treated with 20 ng/ml interleukin-4 (IL-4) (200-04-02; PeproTech, Cranbury, NJ, USA) and 20 ng/ml interleukin-13 (IL-13) (HY- P70568 ; MCE, Monmouth Junction, NJ, USA).

    Techniques: Expressing

    (A) THP-1 cells were infected with shJMJD3 or oeJMJD3 lentiviruses for 72 hours. JMJD3 mRNA expression was then assessed. shCtrl and oeCtrl: negative control lentiviruses. shJMJD3: THP-1 cells infected with lentiviruses to knockdown JMJD3. oeJMJD3: THP-1 cells infected with lentiviruses to overexpress JMJD3. Following lentivirus infection, THP-1 cells were treated with PMA for 24 hours, followed by IL-4 and IL-13 for 48 hours. After this, the medium was replaced by RPMI 1640 medium without FBS for an additional 24 hours. Protein and mRNA were then extracted, and the supernatant was collected. (B) Relative expression of Arg1 mRNA. (C) Concentrations of TNF in the supernatant of different groups of macrophages. (D) Relative expression of IRF4 mRNA. (E, F) Western blot analysis of CD206, JMJD3, and IRF4 protein. The experiments were replicated three times. * p < 0.05, ** p < 0.01, ***p < 0.001, ****p < 0.0001. Abbreviations: JMJD3, Jumonji domain-containing protein 3; Arg1, arginase 1; TNF, tumor necrosis factor; IRF4, interferon regulatory factor 4; CD206, cluster of differentiation 206.

    Journal: PLOS One

    Article Title: JMJD3 regulates the M2-like macrophage polarization and promotes the growth of breast cancer cells via STAT6/IRF4 axis

    doi: 10.1371/journal.pone.0341313

    Figure Lengend Snippet: (A) THP-1 cells were infected with shJMJD3 or oeJMJD3 lentiviruses for 72 hours. JMJD3 mRNA expression was then assessed. shCtrl and oeCtrl: negative control lentiviruses. shJMJD3: THP-1 cells infected with lentiviruses to knockdown JMJD3. oeJMJD3: THP-1 cells infected with lentiviruses to overexpress JMJD3. Following lentivirus infection, THP-1 cells were treated with PMA for 24 hours, followed by IL-4 and IL-13 for 48 hours. After this, the medium was replaced by RPMI 1640 medium without FBS for an additional 24 hours. Protein and mRNA were then extracted, and the supernatant was collected. (B) Relative expression of Arg1 mRNA. (C) Concentrations of TNF in the supernatant of different groups of macrophages. (D) Relative expression of IRF4 mRNA. (E, F) Western blot analysis of CD206, JMJD3, and IRF4 protein. The experiments were replicated three times. * p < 0.05, ** p < 0.01, ***p < 0.001, ****p < 0.0001. Abbreviations: JMJD3, Jumonji domain-containing protein 3; Arg1, arginase 1; TNF, tumor necrosis factor; IRF4, interferon regulatory factor 4; CD206, cluster of differentiation 206.

    Article Snippet: Subsequently, the cells were treated with 20 ng/ml interleukin-4 (IL-4) (200-04-02; PeproTech, Cranbury, NJ, USA) and 20 ng/ml interleukin-13 (IL-13) (HY- P70568 ; MCE, Monmouth Junction, NJ, USA).

    Techniques: Infection, Expressing, Negative Control, Knockdown, Western Blot

    THP-1 cells were first treated with PMA for 24 hours. Following this, AS1517499 (1μM) was administered for 30 minutes, and then the cells were treated with IL-4 and IL-13. 48 hours later, the medium was replaced with RPMI 1640 medium without FBS and cells were incubated for an additional 24 hours. Protein and mRNA were then extracted, and the supernatant was collected. (A) The mRNA expression of Arg1. (B) Concentrations of TNF in the supernatant of different groups of macrophages. (C) Concentrations of IL-10 in the supernatant of different groups of macrophages. (D) Expression of IRF4 mRNA. (E) Expression of JMJD3 mRNA. (F) Western blot analysis of JMJD3, p-STAT6, and IRF4 protein expression. The experiments were replicated three times. * p < 0.05, ** p < 0.01, ***p < 0.001, ****p < 0.0001. Abbreviations: JMJD3, Jumonji domain-containing protein 3; Arg1, arginase 1; TNF, tumor necrosis factor; IRF4, interferon regulatory factor 4; IL-10, interleukin-10; p-STAT6, phosphorylated signal transducer and activator of transcription 6.

    Journal: PLOS One

    Article Title: JMJD3 regulates the M2-like macrophage polarization and promotes the growth of breast cancer cells via STAT6/IRF4 axis

    doi: 10.1371/journal.pone.0341313

    Figure Lengend Snippet: THP-1 cells were first treated with PMA for 24 hours. Following this, AS1517499 (1μM) was administered for 30 minutes, and then the cells were treated with IL-4 and IL-13. 48 hours later, the medium was replaced with RPMI 1640 medium without FBS and cells were incubated for an additional 24 hours. Protein and mRNA were then extracted, and the supernatant was collected. (A) The mRNA expression of Arg1. (B) Concentrations of TNF in the supernatant of different groups of macrophages. (C) Concentrations of IL-10 in the supernatant of different groups of macrophages. (D) Expression of IRF4 mRNA. (E) Expression of JMJD3 mRNA. (F) Western blot analysis of JMJD3, p-STAT6, and IRF4 protein expression. The experiments were replicated three times. * p < 0.05, ** p < 0.01, ***p < 0.001, ****p < 0.0001. Abbreviations: JMJD3, Jumonji domain-containing protein 3; Arg1, arginase 1; TNF, tumor necrosis factor; IRF4, interferon regulatory factor 4; IL-10, interleukin-10; p-STAT6, phosphorylated signal transducer and activator of transcription 6.

    Article Snippet: Subsequently, the cells were treated with 20 ng/ml interleukin-4 (IL-4) (200-04-02; PeproTech, Cranbury, NJ, USA) and 20 ng/ml interleukin-13 (IL-13) (HY- P70568 ; MCE, Monmouth Junction, NJ, USA).

    Techniques: Incubation, Expressing, Western Blot